3 results
The primary objective of this efficacy and safety study is to demonstrate that tight control of disease activity using stringent criteria based on CDAI, hs-CRP, fecal Calprotectin, and corticosteroid use improves the rate of mucosal healing 48 weeks…
x To assess the safety and tolerability of MK-7240/PRA023 in SSc-ILD x To compare the annual rate of change from Baseline in forced vital capacity (FVC), in mL, of MK-7240/PRA023 vs. placebo over 50 weeks For more information please refer to…
The purpose of this study is to determine if the combination of relatlimab and nivolumab improves overall survival (OS) in all randomized participants and participants with PD-L1 CPS >= 1 with later-line metastatic colorectal cancer compared…